

# Oregon Prescription Drug Monitoring Program 2021 3rd Quarter Report



Percentage change evaluated relative to 3rd Quarter, 2020

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



## Summary

- Prescriptions for amphetamine (+ 18%) and methylphenidate (+ 11%) have increased from the 3rd quarter of 2020, while prescriptions for common opioids and benzodiazepines have decreased (Table 5).
- Registration has increased for all user disciplines (Table 4), but especially for NDs (+ 99%).
- Integrated queries and users continue to increase as web queries decrease (Table 1, Table 4), which has been occurring since at least 2020 Q1.
- 22% of opioid prescribers this quarter were responsible for at least one prescription of over 90 morphine milligram equivalents (MME), as shown in the figure below.



† Query data drawn from Appriss AWARxE and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2021 3rd Quarter Report

Percentage change evaluated relative to 3rd Quarter, 2020

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



**Table 1. PDMP Queries Summary Statistics: July-September, 2021**

Measure	Web Portal	% Change*	Integrated	% Change*
<b>Queries †</b>	197,367	- 35.8 %	6,955,876	+ 31 %
<b>Healthcare providers</b>	52,874	- 35.1 %	5,915,256	+ 32.4 %
<b>Pharmacies</b>	45,542	- 36.3 %	1,040,620	+ 23.7 %
<b>Delegates</b>	98,831	- 36 %	-	-

- Web Portal queries have decreased from the same quarter last year across all user groups.
- The number of integrated queries continues to increase.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

**Table 2. Special Requests: July-September, 2021**

Measure	Count
<b>Special Requests Total</b>	73
<b>Patient Records</b>	12
<b>Healthcare Board</b>	56
<b>Law Enforcement</b>	5

- 73 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.

\* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWAxE web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2021 3rd Quarter Report

Percentage change evaluated relative to 3rd Quarter, 2020

healthoregon.org/pdmp



Table 3. PDMP Enrollment and System Use: July-September, 2021

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
<b>All Prescribers</b>	18,590	15,751 / 84.7 %	3,891 / 24.7 %	11,537 / 73.2 %	12,386 / 78.6 %
<b>Top 4K Prescribers</b>	4,000	3,870 / 96.8 %	1,747 / 45.1 %	3,441 / 88.9 %	3,623 / 93.6 %
<b>Top 2K Prescribers</b>	2,000	1,960 / 98 %	995 / 50.8 %	1,771 / 90.4 %	1,857 / 94.7 %

- During the 3rd quarter of 2021 there were 18,590 prescribers who wrote prescriptions for controlled substances in Oregon.
- At the close of the 3rd quarter, 78.6 % of enrolled prescribers queried the system; 93.6 % of the top 4,000 prescribers; 94.7 % of the top 2,000 prescribers through the web portal or integration.
- A much higher percentage of enrolled prescribers are querying the system through an integrated interface (73.2%) as compared to the web (24.7%).

Table 4. PDMP Query by Clinical User Group: July-September, 2021

Discipline	Total User Accounts	% Change*	Web Users <sup>±†</sup>	% Change*	Integrated Users	% Change*
MD/PA/DO	18,813	+ 9.3 %	1,525	- 19.8 %	13,143	+ 8.7 %
NP/CNS-PP	4,874	+ 20.6 %	879	- 7.1 %	3,081	+ 11.7 %
RPh	3,878	+ 2.2 %	1,369	- 12.2 %	400	+ 67.3 %
Delegates	3,386	- 0.8 %	1,628	- 14.2 %	-	-
DDS/DMD	3,354	+ 18.2 %	301	- 30.8 %	248	+ 6.4 %
ND	1,176	+ 99.3 %	120	- 17.2 %	440	+ 10.8 %

- PDMP registration has increased for all prescriber groups, while remaining steady for pharmacists and delegates.
- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing, while integrated users are increasing.

\* Percentage change figures evaluated relative to the same time period during the prior year.

<sup>±</sup> Users that have submitted a query this quarter.

<sup>†</sup> Query data drawn from Appriss AWA<sup>®</sup> and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2021 3rd Quarter Report

Percentage change evaluated relative to 3rd Quarter, 2020

healthoregon.org/pdmp



Table 5. Top Prescriptions: July-September, 2021

Drug	# of Rx	% of all Rx	% Change*
All	1,663,697	100 %	+ 0.1 %
Hydrocodone	235,212	14.1 %	- 7.3 %
Gabapentin	226,479	13.6 %	+ 3.5 %
Oxycodone	221,846	13.3 %	- 4.2 %
Amphetamine	173,318	10.4 %	+ 18 %
Lorazepam	83,122	5 %	- 2.7 %
Tramadol	80,694	4.9 %	- 5.9 %
Methylphenidate	72,859	4.4 %	+ 10.8 %
Zolpidem	65,531	3.9 %	- 5.9 %
Alprazolam	60,333	3.6 %	- 5.3 %
Clonazepam	59,891	3.6 %	- 3.9 %

- Prescriptions for stimulants (i.e., amphetamine, methylphenidate) increased relative to the same quarter last year.
- Oxycodone and hydrocodone prescriptions decreased.
- The number of prescriptions for the most commonly prescribed benzodiazepines decreased, including lorazepam, alprazolam, and clonazepam.
- Prescriptions for gabapentin increased, reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.

Table 6. Prescriptions for Buprenorphine and Naloxone: July-September, 2021

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	22,242	1.3 %	- 44.7 %
Buprenorphine/Naloxone	8,313	0.5 %	- 65.3 %
Naloxone	5,616	0.3 %	+ 33.3 %

- Prescriptions for naloxone have increased while prescriptions for buprenorphine and buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, [pdmp.research@state.or.us](mailto:pdmp.research@state.or.us)

\* Percentage change figures evaluated relative to the same time period during the prior year